This company listing is no longer active
Abcam Past Earnings Performance
Past criteria checks 0/6
Key information
-36.0%
Earnings growth rate
-37.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 8.6% |
| Return on equity | 1.0% |
| Net Margin | 2.1% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Abcam makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 350 | 7 | 178 | 32 |
| 31 Mar 22 | 333 | 6 | 167 | 28 |
| 31 Dec 21 | 315 | 4 | 157 | 24 |
| 30 Jun 21 | 298 | 16 | 153 | 25 |
| 31 Mar 21 | 284 | 7 | 144 | 23 |
| 31 Dec 20 | 295 | 26 | 143 | 27 |
| 30 Sep 20 | 265 | 5 | 125 | 20 |
| 30 Jun 20 | 260 | 13 | 125 | 23 |
| 31 Mar 20 | 267 | 27 | 121 | 22 |
| 31 Dec 19 | 273 | 43 | 102 | 12 |
| 30 Sep 19 | 267 | 44 | 96 | 11 |
| 30 Jun 19 | 260 | 44 | 96 | 15 |
| 31 Mar 19 | 253 | 51 | 89 | 12 |
| 31 Dec 18 | 245 | 58 | 88 | 14 |
| 30 Sep 18 | 239 | 60 | 83 | 15 |
| 30 Jun 18 | 233 | 62 | 78 | 16 |
| 31 Mar 18 | 230 | 59 | 79 | 18 |
| 31 Dec 17 | 227 | 55 | 81 | 19 |
| 30 Sep 17 | 222 | 49 | 80 | 19 |
| 30 Jun 17 | 217 | 42 | 79 | 19 |
| 31 Mar 17 | 206 | 41 | 72 | 18 |
| 31 Dec 16 | 196 | 40 | 66 | 17 |
| 30 Sep 16 | 184 | 39 | 63 | 16 |
| 30 Jun 16 | 172 | 37 | 59 | 14 |
| 31 Mar 16 | 164 | 37 | 55 | 13 |
Quality Earnings: A8C1 has a large one-off loss of £45.1M impacting its June 30 2022 financial results.
Growing Profit Margin: A8C1's current net profit margins (2.1%) are lower than last year (5.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A8C1's earnings have declined by 36% per year over the past 5 years.
Accelerating Growth: A8C1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A8C1 had negative earnings growth (-54.9%) over the past year, making it difficult to compare to the Biotechs industry average (-15.1%).
Return on Equity
High ROE: A8C1's Return on Equity (1%) is considered low.